Discussion
LUTS, hematospermia, prostate
ANEJACULATION, ADVERSE EVENTS, PROSTATE, SECONDARY, BPH
iTind was an effective treatment for LUTS secondary to BPH while preserving sexual function regardless of age, prostate volume, or baseline ED status. ED, as measured by both total SHIM and IIEF scores and when stratifying by age, prostate volume, or baseline ED status, did not change significantly over the 12-month study period. This is in line with 6-month data from a prospective study showing no ED in men treated with iTind.Moreover, iTind was shown to not cause EjD in men, regardless of age, prostate volume, or baseline ED status. Additionally, men without baseline ED had improvement of 21.5% when looking at IIEF question 9 to evaluate for EjD. Importantly, we had no patient-reported ejaculatory adverse events such as anejaculation, decreased ejaculatory volume, painful ejaculation, or hematospermia. Rezum, on the other hand, reported 2.9% anejaculation compared with 0% in their sham arm.Additionally, men who have no baseline ED (SHIM >21) also showed clinically significant improvement of IIEF at 12 months as compared with their baseline (6.07 ± 21.17, Our study has several limitations. First, we experienced loss of follow-up between the baseline groups at 3 months in 29% of iTind patients and 30% of the sham arm. Even though we experienced loss to follow-up, a matched dropout rate between the iTind and sham arm indicates it is likely not a procedure-related drop off. Another important limitation to note is that this study was originally designed to evaluate the change of LUTS following iTind 